EGFR Cancer Research Results

EGFR, Epidermal Growth Factor Receptor: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-Driver
Type: Oncogene
EGFR (Epidermal growth factor receptor), which belongs to the tyrosine kinase receptor family (RTKs)
Epidermal Growth Factor Receptor (EGFR) is a cell surface protein that plays a crucial role in the regulation of cell growth, survival, proliferation, and differentiation. It is part of the ErbB family of receptors and is activated by binding to its ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).

-plays a crucial role in regulating cell growth and division.

Many cancers exhibit overexpression of EGFR, which can lead to enhanced signaling and contribute to tumor growth and survival. This overexpression is often associated with aggressive tumor behavior and poor prognosis.
Scientific Papers found: Click to Expand⟱
4671- CUR,    Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy
- in-vitro, CRC, NA
CSCs↓, TumCG↓, ChemoSen↑, Wnt↓, β-catenin/ZEB1↓, Shh↓, NOTCH↓, DNMT1↓, STAT3↓, NF-kB↓, EGFR↓, IGFR↓, TumCCA↓, cl‑PARP↑, BAX↑, ECM/TCF↓,
6684- DAP,  GB,    Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
- vitro+vivo, NSCLC, H1975
PDK1↓, eff↑, EGFR↓, Apoptosis↑,
1443- Deg,    Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, BT549
EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,
6352- DRE,    Investigation of the Anti-Lung Cancer Mechanisms of Taraxacum officinale Based on Network Pharmacology and Multidimensional Experimental Validation
- in-vitro, Lung, A549 - in-vitro, Nor, L929
other↝, other↝, tumCV↑, selectivity?, EGFR↓, AKT1↓, NQO1↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
6784- EGCG,    Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *cardioP↑, *neuroP↑, *GutMicro↑, *AntiBio↑, *ROS↓, *TNF-α↓, *IL6↓, TumCP↓, *LDL↓, *NO↓, *Obesity↓, *p‑tau↓, *Aβ↓, *NRF2↑, *SOD↑, *Catalase↑, *GPx↑, *NLRP3↓, *mTOR↓, TumCCA↑, NRF2↓, Apoptosis↑, SIRT1↓, miR-25-5p↓, PARP↑, Casp3↑, Casp9↑, ER Stress↑, TumAuto↑, EMT↓, TumCI↓, TumCMig↓, TGF-β↓, Smad1↓, STAT3↓, VEGF↓, angioG↓, Imm↑, EGFR↓, *GutMicro↑, *Bacteria↓, *AntiViral↑, *BioAv↓, *BioAv↑, *eff↑, *BioAv↑, eff↑, ChemoSen↑, *toxicity↝,
26- EGCG,  QC,  docx,    Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
- vitro+vivo, Pca, PC3
BAD↓, cl‑PARP↑, Casp7↑, IκB↓, Ki-67↓, VEGF↓, EGFR↓, FGF↓, TGF-β↓, TNF-α↓, SCF↓, Bax:Bcl2↑, NF-kB↓, chemoP↑, ChemoSen↑, TumVol↓,
20- EGCG,    Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
- in-vivo, Liver, NA - in-vivo, Tong, NA
HH↓, Gli1↓, Smo↓, TNF-α↓, COX2↓, *antiOx↑, Hif1a↓, NF-kB↓, VEGF↓, STAT3↓, Bcl-2↓, P53↑, Akt↓, p‑Akt↓, p‑mTOR↓, EGFR↓, AP-1↓, BAX↑, ROS↑, Casp3↑, Apoptosis↑, NRF2↑, *H2O2↓, *NO↓, *SOD↑, *Catalase↑, *GPx↑, *ROS↓,
643- EGCG,    New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate
- Analysis, NA, NA
H2O2↑, Fenton↑, PDGFR-BB↑, EGFR↓, VEGFR2/KDR/Flk1↓, IGFR↓, Ca+2↑, NO↑, Sp1/3/4↓, NF-kB↓, AP-1↓, STAT1↓, STAT3↓, FOXO↓, mtDam↑, TumAuto↑,
668- EGCG,    The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment
- Review, BC, MCF7 - Review, BC, MDA-MB-231
HER2/EBBR2↓, EGFR↓, mtDam↑, ROS↑, PI3K/Akt↓, P53↑, P21↑, Casp3↑, Casp9↑, BAX↑, PTEN↑, Bcl-2↓, hTERT/TERT↓, STAT3↓, TumCCA↑, Hif1a↓,
670- EGCG,    Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns
- Review, NA, NA
TumCCA↑, P53↑, ERK↓, EGFR↓, p‑ERK↑, VEGF↓, Hif1a↓, miR-203↓, miR-210↑,
649- EGCG,  CUR,  PI,    Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
*BioEnh↑, EGFR↓, HER2/EBBR2↓, IGF-1↓, MAPK↓, ERK↓, RAS↓, Raf↓, NF-kB↓, p‑pRB↓, TumCCA↑, Glycolysis↓, Warburg↓, HK2↓, Pyruv↓,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
2459- EGCG,    Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis
- in-vitro, Tong, Tca8113 - in-vitro, Tong, TSCCa
EGFR↓, Akt↓, ERK↓, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,
6846- EVO,    Evodiamine Inhibits Colorectal Cancer Growth via RTKs Mediated PI3K/AKT/p53 Signaling Pathway
- in-vitro, CRC, HT29 - in-vitro, CRC, HCT116
TumCP↓, TumCI↓, TumCCA↑, PI3K↓, AKT1↓, P53↑, Bcl-2↓, BAX↑, Apoptosis↑, p‑Casp9↑, E-cadherin↑, N-cadherin↓, MMP9↓, CSCs↓, EGFR↓, PDGFRA↓, Dose↝, TumCG↓,
6897- FIS,    Fisetin: A Dietary Antioxidant for Health Promotion
- Review, Nor, NA
*chemoPv↑, *neuroP↑, *antiOx↑, *GSH↑, *HO-1↑, *NRF2↑, angioG↓, TumCG↓, uPA↓, MMP1↓, tumCV↓, PTEN↑, PI3K↓, p‑Akt↓, AMPK↑, mTOR↓, EGFR↓, NF-kB↓, COX2↓, PGE2↓, Wnt↓, β-catenin/ZEB1↓, TCF↓, cycD1/CCND1↓, MMP7↓, RadioS↑, PSA↓, Securin↓, TumCCA↑, XIAP↓, *ERK↑, *p‑CREB↑, *memory↑, *GSH↑, *Inflam↓, *5LO↓,
6912- FIS,    Cancer chemopreventive role of fisetin: Regulation of cell signaling pathways in different cancers
- Review, Var, NA
TumMeta↓, chemoPv↑, VEGF↓, VEGFR1↓, EGFR↓, Necroptosis↑, Hippo↝,
6901- FIS,    Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC
- in-vivo, HNSCC, CAL33
TumCG↓, TumCD↑, selectivity↑, TumCCA↑, CDC25↓, CDK1↓, CycB/CCNB1↓, P53↑, DNAdam↑, Apoptosis↑, γH2AX↑, cl‑PARP↑, other↝, JNK↑, PI3K↓, Akt↓, ERK↓, EGFR↓, STAT3↓, TumAuto↑, Dose↝, TumVol↓, Ki-67↓, cl‑Casp3↑, P21↓, p27↓,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2852- FIS,    A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms
- Review, CRC, NA
Risk↓, P53↑, MDM2↓, COX2↓, Wnt↓, NF-kB↓, CDK2↓, CDK4↓, p‑RB1↓, cycE/CCNE↓, P21↑, NRF2↓, ROS↑, Casp8↑, Fas↑, TRAIL↑, DR5↑, MMP↓, Cyt‑c↑, selectivity↑, P450↝, GSTs↝, RadioS↑, Inflam↓, β-catenin/ZEB1↓, EGFR↓, TumCCA↑, ChemoSen↑,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP/DDIT3↑, eff↑, ChemoSen↑,
2859- FIS,    The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways
- in-vitro, Liver, HepG2 - NA, Colon, Caco-2
TumCG↓, other↝, Casp3↑, Casp7↑, PGE2↓, GSTs↓, Wnt↓, EGFR↓, NF-kB↓, COX2↓, P53↑, P21↑, P450↓,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP/DDIT3↑, ROS↑, cMyc↓, cardioP↑,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
1113- FIS,    Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓, CSCs↓,
6981- Form,    Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
BioAv↝, *memory↑, *ROS↓, *AChE↓, *NF-kB↓, *Keap1↝, *NRF2↑, *Inflam↓, *PGC-1α↝, *HO-1↓, *p‑tau↓, *cognitive↑, *BDNF↑, *5HT↑, *Stroke↓, *PARP1↓, *AIF↓, *Casp3↓, NP/CIPN↓, *neuroP↑, *NGF↑, *TNF-α↓, *IL1β↓, *IL18↓, *IL6↓, *VCAM-1↓, *pol-M2 MC↑, *hepatoP↑, *AST↓, *ALAT↓, *LC3II↑, *Beclin-1↑, *p62↑, *COX2↑, *MMP↑, *ATP↑, *GSH↑, *Catalase↑, *GPx↑, *MDA↓, *antiPs↑, *AntiDiabetic↑, *glucose↓, *Insulin↑, *GutMicro↑, *Obesity↓, COX2↓, cycD1/CCND1↓, TumCCA↑, EGFR↓, GSK‐3β↑, Mcl-1↓, *toxicity↓, TumCP↓, Hif1a↓, VEGF↓, ERK↓, LAMs↓, Cyt‑c↑, Casp9↑, Casp3↑, PARP↑, TumCD↑, mitA↑, BACH1↓, P53↓, ROS↑, PD-1↓, NF-kB↓, *Bacteria↓, *AntiViral↑, *mt-ROS?, *PI3K↓, *chemoP↑, ChemoSen↑, eff↑, *toxicity↓, *BioAv↑, *BioAv↑, *eff↑,
6969- Form,    Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer
- vitro+vivo, NSCLC, HCC827 - in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
EGFR↓, Akt↓, GSK‐3β↑, TumCG↓, ChemoSen↑, Mcl-1↓, RadioS↑, tumCV↓, selectivity↑, Dose↝, Cyt‑c↑, BAX↑, Apoptosis↑, Ki-67↓, toxicity↓, chemoPv↑,
7048- GA,    Natural bioactive gallic acid shows potential anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells
- in-vitro, Var, NA
AntiCan↑, TumCCA↑, angioG↓, TumCMig↓, TumMeta↓, CSCs↓, Apoptosis↑, P21↑, P53↑, p27↑, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, SOX2↓, Nanog↓, OCT4↓, ROS↑, DNAdam↑, BRCA1↑, ATM↑, CHK1↑, Chk2↑, Histones↑, TumCI↓, MMPs↓, EGFR↓, JAK2↓, STAT5↓,
1091- GA,    Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, HTB-35
tumCV↓, TumCP↓, ADAM17↓, EGFR↓, p‑Akt↓, p‑ERK↓,
997- GA,    The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H292 - in-vitro, Nor, HUVECs
PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp↓, survivin↓,
7136- GI,    [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2
- vitro+vivo, NSCLC, H1650
TumCP↓, TumCCA↑, Apoptosis↑, Akt↓, EGFR↓, STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, TumCG↓, Ki-67↓, eff↑, Dose↝,
834- Gra,    Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review
- Review, NA, NA
EGFR↓, PI3K/Akt↓, NF-kB↓, JAK↓, STAT↓, Hif1a↓, GLUT1↓, GLUT4↓, ROS↑, Catalase↑, SOD↑, HO-1↑,
1232- Gra,    Graviola: A Systematic Review on Its Anticancer Properties
- Review, NA, NA
EGFR↓, cycD1/CCND1↓, Bcl-2↓, TumCCA↑, Apoptosis↑, ROS↑, MMP↓, BAX↑, Cyt‑c↑, Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ATP↓,
7169- HDN-1,  CHA,    Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90
- in-vitro, Lung, H1975 - in-vitro, Lung, HCC827 - in-vitro, Lung, A549
HSP90↓, TumCP↓, EGFR↓, STAT3↓, Akt↓, ERK↓, Raf↓, cycD1/CCND1↓, SUV39H↓,
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
2874- HNK,    Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9
- in-vitro, Lung, H1299
MMP9↓, α-tubulin↑, TumCI↓, HDAC6↓, HSP90↓, TumCMig↓, EGFR↓,
2876- HNK,    Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Lung, H23 - in-vitro, Lung, HCC827
EGFR↓, HSP90↓,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoPv↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP/DDIT3↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
2897- HNK,    Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, PC9 - in-vitro, Lung, A549
TumCP↓, Apoptosis↑, EGFR↓, PI3K↓, Akt↓, STAT3↓, TumCI↓, TNF-α↑, NF-kB↓, VEGF↓, MMP9↓, COX2↓,
1787- LE,    Licorice and cancer
- Review, Var, NA
Inflam↓, AntiCan↓, DNAdam↓, LOX1↓, COX2↓, PKCδ↓, EGFR↓,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,

Showing Research Papers: 51 to 100 of 145
Prev Page 2 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 145

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

SUV39H↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   antiOx⇅, 1,   Catalase↑, 1,   CYP1A1↓, 1,   Fenton↑, 1,   GSTs↓, 2,   GSTs↝, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 3,   HO-2↓, 1,   Keap1↓, 1,   lipid-P↓, 1,   NQO1↓, 1,   NRF2↓, 3,   NRF2↑, 3,   ROS↓, 3,   ROS↑, 20,   mt-ROS↑, 1,   SIRT3↑, 1,   SOD↑, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 2,   ATP↓, 1,   CDC2↓, 1,   CDC25↓, 3,   EGF↓, 2,   MEK↓, 1,   mitResp↓, 1,   MMP↓, 8,   mtDam↑, 2,   OCR↓, 1,   Raf↓, 2,   XIAP↓, 4,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 2,   AKT1↓, 2,   AMPK↑, 3,   cMyc↓, 2,   ECAR↝, 1,   FASN↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 3,   Histones↑, 1,   HK2↓, 3,   lactateProd↓, 2,   LDHA↓, 1,   NADPH↓, 1,   PDK1?, 2,   PDK1↓, 1,   PI3K/Akt↓, 3,   cl‑PPARα↓, 1,   Pyruv↓, 1,   SIRT1↓, 3,   SIRT1↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 22,   Akt↑, 1,   p‑Akt↓, 5,   APAF1↑, 1,   Apoptosis↑, 17,   BAD↓, 1,   BAD↑, 2,   BAX↑, 13,   BAX⇅, 1,   Bax:Bcl2↑, 3,   Bcl-2↓, 11,   Bcl-xL↓, 2,   BIM↑, 2,   Casp↑, 3,   Casp3↑, 17,   cl‑Casp3↑, 2,   Casp7↑, 4,   Casp8↑, 6,   cl‑Casp8↑, 1,   Casp9↑, 10,   p‑Casp9↑, 1,   cl‑Casp9↑, 3,   cFLIP↓, 1,   Chk2↑, 1,   Cyt‑c↑, 14,   Diablo↑, 4,   DR4↑, 1,   DR5↑, 5,   FADD↑, 1,   Fas↓, 1,   Fas↑, 3,   FasL↑, 1,   Hippo↝, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   IAP2↓, 1,   iNOS↓, 2,   JNK↓, 1,   JNK↑, 3,   MAPK↓, 4,   MAPK↑, 1,   Mcl-1↓, 8,   MDM2↓, 3,   MDM2↑, 1,   Myc↓, 3,   Necroptosis↑, 1,   NOXA↑, 1,   p27↓, 1,   p27↑, 4,   p38↓, 1,   p38↑, 1,   PUMA↑, 1,   survivin↓, 5,   Telomerase↓, 2,   TRAIL↑, 2,   TumCD↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   HER2/EBBR2↓, 3,   miR-25-5p↓, 1,   Sp1/3/4↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 3,   EZH2↓, 1,   HATs↓, 1,   other↝, 4,   pRB↑, 1,   p‑pRB↓, 1,   tumCV↓, 8,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   eIF2α↑, 1,   ER Stress↑, 6,   GRP78/BiP↑, 2,   HSP27↓, 1,   HSP27↝, 1,   HSP70/HSPA5↓, 2,   HSP70/HSPA5↝, 1,   HSP90↓, 4,   IRE1↑, 1,   p‑PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   BRCA1↑, 1,   CHK1↑, 1,   DNAdam↓, 2,   DNAdam↑, 7,   DNMT1↓, 1,   DNMTs↓, 1,   p16↑, 1,   P53?, 1,   P53↓, 1,   P53↑, 17,   PARP↑, 2,   cl‑PARP↑, 11,   PCNA↓, 2,   SIRT6↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 12,   CDK4↓, 9,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 15,   cycE/CCNE↓, 8,   mitA↑, 1,   P21↓, 1,   P21↑, 12,   p‑RB1↓, 2,   Securin↓, 2,   TumCCA↓, 1,   TumCCA↑, 20,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 3,   CD44↓, 1,   CDK8↓, 1,   cFos↓, 4,   cMET↓, 1,   p‑cMET↑, 1,   CSCs↓, 4,   EMT↓, 8,   ERK↓, 15,   p‑ERK↓, 4,   p‑ERK↑, 1,   FGF↓, 1,   FOXO↓, 1,   FOXO↑, 1,   Gli1↓, 1,   GSK‐3β↑, 2,   HDAC↓, 2,   HDAC6↓, 1,   HH↓, 1,   IGF-1↓, 4,   IGFR↓, 2,   miR-34a↑, 1,   mTOR↓, 13,   p‑mTOR↓, 2,   mTORC1↓, 3,   mTORC2↓, 2,   mTORC2↑, 1,   Nanog↓, 1,   Nestin↓, 2,   NOTCH↓, 2,   OCT4↓, 1,   PDGFRA↓, 1,   PI3K↓, 13,   p‑PI3K↓, 1,   PTEN↑, 5,   RAS↓, 3,   RAS↑, 1,   SCF↓, 1,   Shh↓, 2,   Smo↓, 1,   SOX2↓, 1,   STAT↓, 1,   STAT1↓, 1,   STAT3↓, 13,   p‑STAT3↓, 5,   STAT5↓, 1,   TCF↓, 1,   TCF↑, 1,   TCF-4↓, 1,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 11,   Wnt↓, 12,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 4,   BACH1↓, 1,   Ca+2↑, 5,   Ca+2↝, 1,   E-cadherin↓, 1,   E-cadherin↑, 5,   FAK↓, 3,   p‑FAK↓, 1,   Fibronectin↓, 2,   Ki-67↓, 4,   LAMs↓, 1,   MET↓, 1,   miR-203↓, 1,   MMP1↓, 5,   MMP2↓, 10,   MMP3↓, 2,   MMP7↓, 4,   MMP9↓, 14,   MMPs↓, 2,   N-cadherin↓, 6,   PDGF↓, 2,   PKCδ↓, 4,   Smad1↓, 1,   SMAD3↓, 1,   Snail↓, 5,   TGF-β↓, 4,   TIMP2↑, 1,   TumCA↓, 1,   TumCI↓, 13,   TumCMig↓, 10,   TumCP↓, 12,   TumMeta↓, 7,   Twist↓, 4,   uPA↓, 8,   VEGFR1↓, 1,   Vim↓, 4,   Zeb1↓, 1,   ZO-1↑, 1,   α-tubulin↑, 1,   β-catenin/ZEB1↓, 8,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 13,   ATF4↓, 1,   ATF4↑, 1,   ECM/TCF↓, 1,   EGFR↓, 49,   p‑EGFR↓, 1,   Endoglin↑, 1,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 9,   LOX1↓, 1,   miR-210↑, 1,   NO↓, 1,   NO↑, 1,   NO↝, 1,   PDGFR-BB↑, 1,   VEGF↓, 17,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,   BBB↑, 1,   GLUT1↓, 2,   GLUT4↓, 2,   NHE1↓, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2↓, 18,   CXCR4↓, 1,   IL1β↓, 1,   IL6↓, 2,   Imm↑, 1,   Inflam↓, 6,   IκB↓, 1,   JAK↓, 2,   JAK1↓, 1,   JAK2↓, 2,   NF-kB↓, 31,   NF-kB↑, 1,   p65↓, 1,   PD-1↓, 1,   PD-L1↓, 2,   PGE2↓, 7,   PSA↓, 1,   TNF-α↓, 6,   TNF-α↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 5,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 3,   BioAv↝, 2,   ChemoSen↑, 15,   CYP1A2↓, 1,   Dose↑, 1,   Dose↝, 6,   Dose∅, 1,   eff↓, 1,   eff↑, 11,   Half-Life↝, 3,   P450↓, 2,   P450↝, 1,   RadioS↑, 8,   selectivity?, 1,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   BMPs↑, 1,   BRCA1↑, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 49,   p‑EGFR↓, 1,   EZH2↓, 1,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 1,   IL6↓, 2,   Ki-67↓, 4,   Myc↓, 3,   PD-L1↓, 2,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 4,   cardioP↑, 1,   chemoP↑, 4,   chemoPv↑, 3,   NP/CIPN↓, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 2,   TumVol↓, 2,  
Total Targets: 350

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 8,   Catalase↑, 5,   GPx↑, 3,   GSH↑, 4,   GSR↑, 1,   GSTA1↑, 1,   H2O2↓, 1,   HO-1↓, 1,   HO-1↑, 2,   Keap1↝, 1,   MDA↓, 1,   NRF2↑, 5,   ROS↓, 10,   mt-ROS?, 1,   SOD↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↓, 1,   ATP↑, 1,   Insulin↑, 1,   MMP↑, 1,   PGC-1α↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   p‑CREB↑, 1,   glucose↓, 1,   LDL↓, 1,   NADPH↓, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

p16↓, 1,   P53↓, 1,   PARP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   mTOR↓, 1,   PI3K↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   p‑Rac1↓, 1,   VCAM-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 2,  

Barriers & Transport(tgid=15) ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   COX2↑, 1,   IKKα↑, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 3,   Inflam↓, 7,   pol-M2 MC↑, 1,   NF-kB↓, 2,   PGE2↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 1,   BDNF↑, 1,   NGF↑, 1,   p‑tau↓, 2,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 4,   BioEnh↑, 1,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALP↓, 1,   AST↓, 2,   GutMicro↑, 3,   IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   antiPs↑, 1,   cardioP↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   memory↑, 2,   neuroP↑, 7,   Obesity↓, 2,   RenoP↑, 1,   toxicity↓, 4,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 2,   Bacteria↓, 2,  
Total Targets: 88

Scientific Paper Hit Count for: EGFR, Epidermal Growth Factor Receptor
14 Fisetin
11 Curcumin
10 EGCG (Epigallocatechin Gallate)
10 Quercetin
8 Honokiol
6 Shikonin
5 Silymarin (Milk Thistle) silibinin
4 almonertinib
4 Berberine
4 Resveratrol
3 Artemisinin
3 Bufalin/Huachansu
3 brusatol
3 Gallic acid
3 Luteolin
3 Sulforaphane (mainly Broccoli)
2 Alpha-Lipoic-Acid
2 Apigenin (mainly Parsley)
2 Betulinic acid
2 Brucea javanica
2 cetuximab
2 chaetocin
2 gefitinib, erlotinib
2 Docetaxel
2 Ursolic acid
2 Formononetin
2 Graviola
2 Magnetic Fields
2 Nimbolide
2 Piperlongumine
1 Astragalus
1 Silver-NanoParticles
1 Allicin (mainly Garlic)
1 Ashwagandha(Withaferin A)
1 Astaxanthin
1 Aloe anthraquinones
1 Biochanin A
1 Chemotherapy
1 Boron
1 α-Bisabolol / Chamomile oil
1 Capsaicin
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Carvacrol
1 Thymol-Thymus vulgaris
1 Chlorogenic acid
1 Chrysin
1 Crocetin
1 Radiotherapy/Radiation
1 Photodynamic Therapy
1 Dichloroacetophenone(2,2-)
1 Deguelin
1 Dandelion Root
1 Ellagic acid
1 Piperine
1 Evodiamine
1 Gambogic Acid
1 Ginger/6-Shogaol/Gingerol
1 epipolythiodioxopiperazine / epipolythiopiperazine-2,5-dione
1 Licorice
1 Lycopene
1 Myricetin
1 Naringin
1 Niclosamide (Niclocide)
1 Phenethyl isothiocyanate
1 Gold NanoParticles
1 Rosmarinic acid
1 Gemcitabine (Gemzar)
1 statins
1 Citric Acid
1 Thymoquinone
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:94  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page